Dr Jerome Boyd-Kirkup

Hummingbird Bioscience is an innovative Singapore biotechnology company that is pioneering the discovery of breakthrough antibody therapies for difficult-to-treat indications. Dr Jerome Boyd-Kirkup is responsible for overseeing the development of new technologies and intellectual property, designing experimental strategies for drug discovery, leading the development and testing of novel therapeutics, and overseeing the drug pipeline. Hummingbird was founded in 2015 and has built a world-class team of 30 staff in Singapore, supported by a deeply experienced international board and scientific advisory panel including 2018 Nobel Laureate in Medicine, James P Allison. To date, Hummingbird has raised more than USD60 million, which has fueled the development of a pipeline of exciting new antibody drugs. Human trials of the first two anti-cancer drugs are scheduled for 2020.

Leave a Comment

Speaker Details